Free Trial

Biomea Fusion (BMEA) Competitors

Biomea Fusion logo
$1.38 -0.06 (-4.17%)
Closing price 10/23/2025 04:00 PM Eastern
Extended Trading
$1.40 +0.02 (+1.45%)
As of 10/23/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BMEA vs. EOLS, BNTC, YMAB, KMDA, TVRD, IMAB, DSGN, IVVD, AMRN, and UPXI

Should you be buying Biomea Fusion stock or one of its competitors? The main competitors of Biomea Fusion include Evolus (EOLS), Benitec Biopharma (BNTC), Y-mAbs Therapeutics (YMAB), Kamada (KMDA), Tvardi Therapeutics (TVRD), I-Mab (IMAB), Design Therapeutics (DSGN), Invivyd (IVVD), Amarin (AMRN), and Upexi (UPXI). These companies are all part of the "pharmaceutical products" industry.

Biomea Fusion vs. Its Competitors

Biomea Fusion (NASDAQ:BMEA) and Evolus (NASDAQ:EOLS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.

96.7% of Biomea Fusion shares are owned by institutional investors. Comparatively, 90.7% of Evolus shares are owned by institutional investors. 18.4% of Biomea Fusion shares are owned by company insiders. Comparatively, 5.9% of Evolus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Biomea Fusion presently has a consensus target price of $9.50, suggesting a potential upside of 588.41%. Evolus has a consensus target price of $21.25, suggesting a potential upside of 214.81%. Given Biomea Fusion's stronger consensus rating and higher probable upside, equities analysts plainly believe Biomea Fusion is more favorable than Evolus.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biomea Fusion
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.78
Evolus
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

In the previous week, Biomea Fusion had 1 more articles in the media than Evolus. MarketBeat recorded 2 mentions for Biomea Fusion and 1 mentions for Evolus. Biomea Fusion's average media sentiment score of 0.82 beat Evolus' score of 0.00 indicating that Biomea Fusion is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Biomea Fusion
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Evolus
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Biomea Fusion has a net margin of 0.00% compared to Evolus' net margin of -22.31%. Biomea Fusion's return on equity of -243.95% beat Evolus' return on equity.

Company Net Margins Return on Equity Return on Assets
Biomea FusionN/A -243.95% -140.74%
Evolus -22.31%-759.04%-24.63%

Evolus has higher revenue and earnings than Biomea Fusion. Evolus is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biomea FusionN/AN/A-$138.43M-$3.03-0.46
Evolus$266.27M1.64-$50.42M-$0.98-6.89

Biomea Fusion has a beta of -0.12, suggesting that its share price is 112% less volatile than the S&P 500. Comparatively, Evolus has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500.

Summary

Biomea Fusion beats Evolus on 11 of the 16 factors compared between the two stocks.

Get Biomea Fusion News Delivered to You Automatically

Sign up to receive the latest news and ratings for BMEA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMEA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BMEA vs. The Competition

MetricBiomea FusionMED IndustryMedical SectorNASDAQ Exchange
Market Cap$85.69M$3.43B$6.18B$10.59B
Dividend YieldN/A2.26%5.72%4.86%
P/E Ratio-0.4623.4029.6728.46
Price / SalesN/A481.70579.41225.02
Price / CashN/A44.5736.5560.64
Price / Book0.9710.3512.076.53
Net Income-$138.43M-$52.53M$3.32B$276.75M
7 Day Performance-8.61%0.25%0.64%0.93%
1 Month Performance-33.01%8.98%5.17%1.41%
1 Year Performance-88.06%11.56%61.77%31.59%

Biomea Fusion Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BMEA
Biomea Fusion
3.5439 of 5 stars
$1.38
-4.2%
$9.50
+588.4%
-87.8%$85.69MN/A-0.4650Gap Up
EOLS
Evolus
3.8675 of 5 stars
$6.00
-2.3%
$21.25
+254.2%
-56.8%$397.17M$266.27M-6.12170
BNTC
Benitec Biopharma
1.3052 of 5 stars
$15.00
+0.5%
$24.80
+65.3%
+47.3%$391.66M$80K-10.2020
YMAB
Y-mAbs Therapeutics
1.393 of 5 stars
$8.61
flat
$9.62
+11.8%
N/A$391.24M$87.68M-17.22150
KMDA
Kamada
4.4966 of 5 stars
$6.88
+1.2%
$13.00
+89.0%
+28.3%$391.03M$160.95M20.24360News Coverage
TVRD
Tvardi Therapeutics
2.7704 of 5 stars
$6.69
-83.9%
$46.17
+590.1%
N/A$390.10M$7.14M0.0080High Trading Volume
IMAB
I-Mab
2.9296 of 5 stars
$5.79
+21.4%
$7.33
+26.7%
+230.1%$389.52M$3.89M0.00380High Trading Volume
DSGN
Design Therapeutics
0.4412 of 5 stars
$6.49
-3.9%
N/A+0.7%$384.40MN/A-5.7940
IVVD
Invivyd
3.8971 of 5 stars
$1.88
+6.8%
$5.14
+173.3%
+96.3%$377.36M$25.38M-2.04100
AMRN
Amarin
0.9586 of 5 stars
$19.17
+5.2%
$12.00
-37.4%
+68.2%$377.05M$228.61M-5.22360News Coverage
Upcoming Earnings
UPXI
Upexi
1.9818 of 5 stars
$6.48
+2.0%
$15.50
+139.2%
+37.1%$373.94M$15.81M0.00130Positive News
Gap Down

Related Companies and Tools


This page (NASDAQ:BMEA) was last updated on 10/24/2025 by MarketBeat.com Staff
From Our Partners